Gilead to Acquire Ouro for $2.1B Autoimmune Pipeline Boost
FOSTER CITY, CALIFORNIA, March 24, 2026 Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FOSTER CITY, CALIFORNIA, March 24, 2026 Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a...
SAN FRANCISCO, Feb. 13, 2026 — Nektar Therapeutics announced the successful closing of a $460 million underwritten public offering,...
BEIJING, China — December 23, 2025 — InnoCare Pharma has announced a major clinical development milestone with the approval...
Dateline — WALTHAM, Mass., November 11, 2025:Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company dedicated to developing...
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
Lake Worth, FL. & New York, August 23, 2025 – Thomas H. Lee Partners (THL) has entered into a...
August 8, 2025 — London, UK. BioNTech SE has reached an agreement with CureVac to receive a non-exclusive license...
NORTH CHICAGO, IL. and SAN DIEGO, CA, August 19, 2025 – AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (“Capstan”),...
